| 초록 |
Antibody Fc domain dictates therapeutic potency and circulating serum half-life of monoclonal IgG antibody by the interaction with the Fc ligands including FcγRs, C1q, and FcRn. To overcome the limitation of conventional monoclonal antibodies used in the clinic, researcher’s growing interest and engineering efforts in the last several years opened a new gateway to transformed IgG Fc into a highly evolvable unit for a new desired function. To enhance therapeutic potency and circulating half-life, various biomolecular, cellular and evolutionary approaches have been employed and will be discussed. |
